Trial Profile

A Phase II Study of AK112 With or Without AK117 for Patients With Metastatic Colorectal Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Ivonescimab (Primary) ; Ligufalimab (Primary) ; Oxaliplatin (Primary)
Indications Adenocarcinoma; Colorectal cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Akeso Biopharma

Most Recent Events

27 Feb 2025 Number of treatment arms are increased from 6 to 11 by the addition of 5 more experimental treatment arms, namely- Expansion Stage Group C, D, E, F and G, Part 2 cohort 1 and Part 2 cohort 2.
27 Feb 2025 Planned number of patients changed from 104 to 254.
27 Feb 2025 Planned End Date changed from 25 Dec 2026 to 12 Aug 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com